EU Implementation of the Nagoya Protocol
Guidance on Scope and Utilization

WDCM 50th. Anniversary; Beijing, 6. –
Dr. Axel Braun
Content

• EU Implementing Legislation
• Guidance on Scope and Core Obligations
• Sector Specific Guidance
• Challenges for Users
EU Implementing Legislation

- **Nagoya Protocol** on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits arising from their Utilization to the CBD (in force since 12.10.2014)
- **EU Regulation No. 511/2014** on compliance measures for users from the Nagoya Protocol (in force since 12.10.2014, except Arts. 4, 7 and 9 one year later)
- **Commission Implementing Regulation (EU) 2015/1866** (in force since 2.11.2015) on Registered Collections; Due Diligence Declarations at the stage of research funding and final development of a product; Best Practice
- **National Law** in EU Member States in force on compliance (sanctions) in: United Kingdom; Germany; Denmark; Slovakia, Hungaria and Croatia and in addition on access in Spain
Guidance on the Scope of Application and Core Obligations of EU No. 511/2014

- Commission Notice (2016/C 313/01), published on 27.8.2016 – legally non-binding

- Scope
  - Geographic: provider countries (country of origin’s) access law
  - Temporal: accessed after 12.10.2014 in provider country
  - Material:
    - Genetic Resources
      - functional units of heredity = genes
      - genetic material - digital sequence data out of scope
    - Commodities: only if utilized in scope
    - Pathogens: only if intentionally accessed (acquired) in scope
    - Derivatives: only in scope if access is combined with access to genetic resource
Commission Notice (2016/C 313/01)

- **Obligations of Users**
  - Users shall exercise *due diligence* to ascertain that genetic resources and *associated traditional knowledge* which they *utilize* have been accessed in accordance with relevant ABS legislation… (Art. 4 EU 511/2014)
  - «Utilization»:
    - «R&D on the genetic and/or biochemical composition of genetic resources» (Art. 2 EU 511/2014)
    - no definition of R&D in the Protocol nor EU Regulation:
      - ordinary meaning (Oxford Dictionary)
      - OECD’s Frascati Manual (five criteria: novel, creative, uncertain, systematic, transferable / reproducible)
      - some general examples are provided, e.g. testing/reference tools
      - sector specific examples in the Sector Specific Guidance
  
- **Territorial application**: EU
Sector Specific Guidance

- **Seven sectors**: animal breeding, bio control/stimulants, biotech, cosmetics, food & feed, pharmaceutical and plant breeding

- **Case studies** (in; out; border-line) along the research and development chains of the different sectors should illustrate the understanding and applicability of the term *utilization* of genetic resources
  - Proposed by sectorial **experts** designated by the Commission

- **Process**: meeting of the sectorial experts to develop 1st. draft; followed by broader stakeholder meetings; revised drafts, incl. feedback from Commission & EU Member States; review by experts; finalization of Guidelines in Q1,2/2017 by the Commission

- **Legal status**: non - binding
Challenges for Users – Recommendations

• **Legal certainty** on access legislation in provider countries: supposed to be on the ABS – Clearing House Internet site (Art. 14 Nagoya Protocol)
  
  *Global Catalogue:* provide key elements or links to such legislation to facilitate user’s compliance with the Nagoya Protocol

• **Temporal trigger** of access legislation
  
  *Global Catalogue:* indicate if access or utilization triggers ABS obligations

• **Public information** of genetic resources
  
  *Global Catalogue:* indicate if public information (sequence or other structural information) triggers ABS obligations

• **Pathogens** with emergency potential for health and food/feed safety
  
  *TRUST as model:* provide for «Fast-track» procedures for access and «Regularizing procedures» for PIC/MAT
Doing now what patients need next